新型注射剂诱导脂肪细胞自我破坏

台湾生物制药公司Caliway开发的实验性注射剂CBL-514在早期人体试验中表现出显著的减脂效果1。该药物通过诱导脂肪细胞凋亡（自我破坏）来降低皮下脂肪和内脏脂肪1。

在第二阶段临床试验中，试验参与者的BMI为22-30 kg/m²，平均年龄在36.4至42.4岁之间，每三周注射一次，疗程最长12周，最高剂量600毫克1。八周后，69.6%的CBL-514治疗组参与者皮下脂肪减少至少150毫升，而安慰剂组无人达到该阈值1。在内脏脂肪方面，四周后CBL-514治疗组内脏脂肪体积平均减少12.01%，而安慰剂组增加5.68%1。八至十二周的随访期间，CBL-514组内脏脂肪体积仍比基线低10.45%，安慰剂组则增加11.76%1。

动物研究表明，CBL-514与糖尿病肥胖症药物替泽帕肽联用能产生比单独使用替泽帕肽更大的体重减轻效果1。参与研究的教授Timothy Garvey表示："我们预计患者会对腹部更平坦等美容效果感到满意，但体重减少、内脏脂肪减少以及血压、胆固醇的改善对健康更为重要1。"该药物可能有助于预防患者停用GLP-1受体激动剂药物后的体重反弹1。第三阶段临床试验招募已在进行中，初步结果预计在随后一年年底前公布1。

Researchers have developed an experimental injection called CBL-514 that triggers fat cell death, with early human trials demonstrating significant reductions in both subcutaneous and visceral fat.1 The drug was created by Caliway Biopharmaceutical, a company based in New Taipei, Taiwan, and findings were presented at the European Association for the Study of Diabetes annual conference.1 In phase two clinical trials, 69.6% of participants treated with CBL-514 achieved at least 150 milliliters of subcutaneous fat reduction after eight weeks, compared to zero participants in the placebo group.1

The treatment showed particularly striking effects on visceral fat, the dangerous fat that accumulates around organs.1 After four weeks, the CBL-514 group experienced an average 12.01% reduction in visceral fat volume, while the placebo group saw an increase of 5.68%—a difference of 17.69 percentage points.1 This advantage persisted at eight to twelve-week follow-up, with the CBL-514 group maintaining a 10.45% reduction below baseline while the placebo group's visceral fat increased by 11.76%.1 Trial participants had a body mass index between 22 and 30 kg/m² and an average age ranging from 36.4 to 42.4 years, receiving injections every three weeks for up to twelve weeks at doses up to 600 milligrams.1

Animal studies indicated that combining CBL-514 with tirzepatide, a diabetes and obesity medication, produced greater weight loss than tirzepatide alone.1 Professor Timothy Garvey noted that while patients may appreciate cosmetic improvements such as a flatter abdomen, "weight reduction, visceral fat reduction and improvements in blood pressure and cholesterol are more important for health."1 Phase three clinical trials are currently recruiting participants, with preliminary results expected by the end of the following year.1